IPP Bureau
NATCO announces tentative approval to its ANDA for Trabectedin
By IPP Bureau - August 18, 2022
According to industry sales data, Yondelis generated annual sales of $49.7 million for the twelve months ending June 2022 in the US market.
ProBioGen enters into master service agreement with NextPoint Therapeutics
By IPP Bureau - August 18, 2022
The integrated services ensure that NextPoint can bring their molecule to the clinic in a timely manner.
Sanofi updates on amcenestrant clinical development program
By IPP Bureau - August 18, 2022
The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial
Philips CEO Frans van Houten to step down; Roy Jakobs named successor
By IPP Bureau - August 18, 2022
The Supervisory Board has unanimously decided to propose Roy Jakobs as the next President and CEO of Royal Philips to its General Meeting of Shareholders.
Abbott’s blood test for concussion could predict outcomes from brain injury and inform treatment interventions
By IPP Bureau - August 18, 2022
The study concluded that elevated levels of two proteins help predict how a person will recover from a traumatic brain injury (TBI), providing important information to determine appropriate care
Sun Pharma gets OAI from USFDA for Halol facility
By IPP Bureau - August 18, 2022
The OAI classification implies that the US FDA may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved
FDA accepts submission of olaparib in combination with abiraterone and prednisone for prostate cancer
By IPP Bureau - August 17, 2022
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Merck and Orna Therapeutics collaborate to advance Orna’s nextgen RNA technology
By IPP Bureau - August 17, 2022
Collaboration supports multiple discovery efforts, including vaccines
ResMed Q4 revenue up 4%; operating profit up 6%
By IPP Bureau - August 16, 2022
The card-to-cloud device was launched into the U.S. and many other markets and is designed to work without an embedded communications module.
Short Wave Pharma signs clinical trial agreement with the Sheeba Research Fund
By IPP Bureau - August 16, 2022
The Trial, the first of its kind in Israel, recently obtained approval from the Israeli Ministry of Health and is preparing for participant recruitment.
NGL Fine-Chem planning greenfield expansion at Tarapur
By IPP Bureau - August 16, 2022
The estimated capex is to the tune of Rs. 140 crore to be funded through debt and internal accrual
Marksans Pharma posts Q1FY23consolidated PAT at Rs. 59.71 Cr
By IPP Bureau - August 16, 2022
The company has reported total income of Rs. 450.26 crores during the period ended June 30, 2022.
Kwality Pharmaceuticals Q1FY23 profit at Rs. 10.52 Cr
By IPP Bureau - August 16, 2022
The company has reported total income of Rs. 70.59 crores during the period ended June 30, 2022.
Lupin receives approval from U.S. FDA for Meclizine Hydrochloride Tablets USP
By IPP Bureau - August 16, 2022
Meclizine Hydrochloride Tablets had estimated annual sales of USD 29 million in the U.S.
Wockhardt announces successful initiation of Global Phase 3 Clinical Study of its novel antibiotic WCK 5222
By IPP Bureau - August 16, 2022
WCK 5222 is a Super-drug which is entirely a new class of antibiotic known as "?-lactam ENHANCER".
